Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease

• Published in: Alzheimer's & dementia Vol. 18; no. 10; pp. 1788 - 1796
• Main Authors: De Kort, Anna M., Kuiperij, H. Bea, Kersten, Iris, Versleijen, Alexandra A.M., Schreuder, Floris H.B.M., Van Nostrand, William E., Greenberg, Steven M., Klijn, Catharina J.M., Claassen, Jurgen A.H.R., Verbeek, Marcel M.
• Format: Journal Article
• Language: English
• Published: United States John Wiley and Sons Inc 01.10.2022
• Subjects: Alzheimer Disease - cerebrospinal fluid; Alzheimer's disease; biomarkers; Biomarkers - cerebrospinal fluid; blood–brain barrier; cerebral amyloid angiopathy; Cerebral Amyloid Angiopathy - cerebrospinal fluid; cerebrospinal fluid; Cognitive Dysfunction - cerebrospinal fluid; Humans; Peptide Fragments - cerebrospinal fluid; pericytes; platelet‐derived growth factor receptor‐β; Receptor, Platelet-Derived Growth Factor beta; tau Proteins - cerebrospinal fluid; blood-brain barrier; cerebral amyloid angiopathy; biomarkers; pericytes; cerebrospinal fluid; platelet-derived growth factor receptor-β; Alzheimer's disease
• ISSN: 1552-5260; 1552-5279
• DOI: 10.1002/alz.12506

Background: Cerebrospinal fluid (CSF) platelet‐derived growth factor receptor‐β (PDGFRβ) has been proposed as a biomarker of blood–brain barrier (BBB) breakdown. We studied PDGFRβ levels as a biomarker for cerebral amyloid angiopathy (CAA), amnestic mild cognitive impairment (aMCI), or Alzheimer's disease (AD). Methods: CSF PDGFRβ levels were quantified by enzyme‐linked immunosorbent assay in patients with CAA, patients with aMCI/AD, and in matched controls. In aMCI/AD we evaluated CSF PDGFRβ both by clinical phenotype and by using the AT(N) biomarker classification system defined by CSF amyloid (A), tau (T), and neurodegeneration (N) biomarkers. Results: PDGFRβ levels were similar in CAA patients and controls (P = .78) and in aMCI/AD clinical phenotype and controls (P = .91). aMCI/AD patients with an AD+ biomarker profile (A+T+[N+]) had increased PDGFRβ levels compared to (A–T–[N–]) controls (P = .006). Conclusion: Our findings indicate that PDGFRβ levels are associated with an AD+ biomarker profile but are not a suitable biomarker for CAA or aMCI/AD clinical syndrome.